Scrip is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Gene Therapies

Payers Must Brace For Coming Wave Of Cell And Gene Therapies

One regenerative medicine for an ultra-rare disease may have a small impact, but payers will be flooded with dozens of new cell and gene therapies over the next few years. Enzyvant, Novartis and Spark share how they are positioning their complex products.
Gene Therapy Reimbursement Pricing Strategies

Latest From Gene Therapy & Regenerative Medicine

Novartis Q3 Preview: Zolgensma Back In The Spotlight

Analysts will be keen to hear about the launches of key new drugs Zolgensma and Mayzent as they ponder how long sales of Cosentyx can keep climbing.

Sales & Earnings Commercial

Dainippon’s Cynata Quest Falls Through As Sides Remain Apart

Japanese firm backs off potential acquisition of Australian cell therapy venture after the two sides fail to agree on deal terms.

M & A Regenerative Medicine

Shake It Off? Japan Mulls Routes Out Of Bioventure Doldrums

The long-recurring theme of how effectively to foster Japan’s bioventure sector again emerged as a key thread at recent major industry meeting, while the broader topic of effective partnering occupied the minds of industry and academia alike.

Japan Gene Therapy

Mystery Solved? GenSight’s Gene Therapy Does Move Between Eyes

Company boosted by animal study which helps answer riddle of improvement in untreated eye.

Ophthalmic Gene Therapy

Audentes' Gene Therapy Allows Ventilator Independence For Rare Disease

Audentes Therapeutics is aiming for regulatory submissions next year for its lead product, a skeletal muscle-targeted gene therapy, which continues to show promise in X-linked myotubular myopathy.

 

 

Rare Diseases Gene Therapy

Progress Being Made With Cell And Gene Therapy Market Access, But Challenges Remain

Drug developers and payers are coming together long before product approvals to work out payment options for high-cost, high-impact cell and gene therapies, but challenges like portability of commercially insured patients and Medicaid best price requirements remain.

Reimbursement Market Access
See All
UsernamePublicRestriction

Register

Advertisement